⌕
Pacific Biosciences of California · PACB · Nasdaq
Tenet 40 · Weak
Compare
$1.84−6.12%At closeTenet 40 · Weak
$1.84−0.12 (−6.12%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Pacific Biosciences of California (PACB) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Zacks Investment ResearchNov 16, 2026 · 10:56 ETEARNINGS EXPECTED BY FEB 12
Here's Why Pacific Biosciences (PACB) Is a Great 'Buy the Bottom' Stock Now

Pacific Biosciences (PACB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend rever…

● Seeking AlphaNov 5, 2026 · 22:05 ETEARNINGS EXPECTED BY FEB 12
Pacific Biosciences Q3: Another Revenue Guidance Cut

Pacific Biosciences reported mixed Q3 results, with revenues beating reduced estimates but gross margins falling. Despite continually declining street revenue estimates, management was disappointed with guidance as it tr…

● Seeking AlphaNov 4, 2026 · 22:54 ETEARNINGS EXPECTED BY FEB 12
Pacific Biosciences of California, Inc. (PACB) Q3 2026 Earnings Call Transcript

Pacific Biosciences of California, Inc. (PACB) Q3 2026 Earnings Call Transcript…

● Zacks Investment ResearchNov 4, 2026 · 20:46 ETEARNINGS EXPECTED BY FEB 12
Pacific Biosciences of California (PACB) Reports Q3 Loss, Beats Revenue Estimates

Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.12 per share a year ago.…

● MarketBeatNov 4, 2026 · 18:14 ETEARNINGS EXPECTED BY FEB 12
What Pacific Biosciences of California (PACB) Said on Its Q3 Earnings Call

Pacific Biosciences of California NASDAQ: PACB reported 6% revenue growth for the third quarter of 2026 as customers adopted its SPRQ-Nx sequencing chemistry, though consumables revenue declined from a year earlier and a…

● GlobeNewsWireNov 4, 2026 · 16:05 ETEARNINGS EXPECTED BY FEB 12
PacBio Announces Third Quarter 2026 Financial Results

MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2026.…

● Zacks Investment ResearchOct 29, 2026 · 19:16 ET
Pacific Biosciences of California (PACB) Rises As Market Takes a Dip: Key Facts

In the latest trading session, Pacific Biosciences of California (PACB) closed at $2.9, marking a +2.47% move from the previous day.…

● GlobeNewsWireOct 27, 2026 · 16:05 ET
PacBio to Participate in Upcoming Investor Conferences

MENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the followi…

● Zacks Investment ResearchOct 27, 2026 · 15:31 ET
Here's Why You Should Hold PacBio Stock in Your Portfolio for Now

PACB's growing clinical adoption, advanced sequencing technologies and rising consumables sales support growth, but funding headwinds and margin pressures persist.…

● Zacks Investment ResearchOct 22, 2026 · 19:16 ET
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors

The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.06, representing a -3.74% change from its previous close.…

● Zacks Investment ResearchOct 14, 2026 · 19:16 ET
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors

In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.99, indicating a -2.93% shift from the previous trading day.…

● GlobeNewsWireOct 14, 2026 · 16:05 ETEARNINGS EXPECTED BY FEB 12
PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026

MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2026 financial results on Wednesday, November 4, 20…

● Zacks Investment ResearchOct 13, 2026 · 13:30 ET
PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics

PACB partners with TychoBio to harness AI and long-read RNA sequencing for rare disease therapies, aiming to improve drug efficacy and safety through advanced data models.…

● Defense WorldOct 12, 2026 · 11:23 ET
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Down – Here’s Why

Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) shares gapped down before the market opened on Monday. The stock had previously closed at $2.33, but opened at $2.24. Pacific Biosciences of Califo…

● Defense WorldOct 11, 2026 · 05:39 ET
Insider Selling: Pacific Biosciences of California (NASDAQ:PACB) Insider Sells $2,058,244.65 in Stock

Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) insider James Gibson II sold 661,815 shares of Pacific Biosciences of California stock in a transaction that occurred on Tuesday, October 6th. The …

● Zacks Investment ResearchOct 8, 2026 · 19:16 ET
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today

The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.3, representing a -15.44% change from its previous close.…

● Zacks Investment ResearchOct 2, 2026 · 19:15 ET
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts

Pacific Biosciences of California (PACB) concluded the recent trading session at $2.54, signifying a +1.2% move from its prior day's close.…

● Schaeffers ResearchOct 1, 2026 · 11:44 ET
3 Biotech Stocks Put Traders Are Targeting Today

Nektar Therapeutics (NASDAQ:NKTR), Quantum-Si Inc (NASDAQ:QSI), and Pacific Biosciences of California Inc (NASDAQ:PACB) are all attracting elevated options activity today, as biotech stocks make volatile moves.…

● Defense WorldOct 1, 2026 · 03:42 ET
Pacific Biosciences of California (NASDAQ:PACB) Stock Sees Heavy Call Option Buying

Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock investors acquired 13,687 call options on the stock. This represents an in…

● Defense WorldSep 30, 2026 · 06:21 ET
Pacific Biosciences of California (NASDAQ:PACB) Shares Climb 6.1% – Still a Buy?

Shares of Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) rose 6.1% on Monday. The company traded as high as $1.68 and last traded at $1.7190. 2,798,059 shares traded hands during mid-day trading…

● Zacks Investment ResearchSep 25, 2026 · 19:15 ET
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know

In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.62, marking a +2.53% move from the previous day.…

● MarketBeatSep 20, 2026 · 02:03 ET
Pacific Biosciences Targets Clinical Growth, $40M Savings With HiFi Sequencing Push

Pacific Biosciences of California NASDAQ: PACB is maintaining its existing strategy while sharpening execution around clinical genomics, cost controls and the rollout of products designed to improve sequencing economics,…

● Zacks Investment ResearchSep 17, 2026 · 19:15 ET
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today

In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.38, indicating a +2.99% shift from the previous trading day.…

● GlobeNewsWireSep 3, 2026 · 16:05 ET
PacBio to Participate in the Morgan Stanley 24ᵗʰ Annual Global Healthcare Conference

MENLO PARK, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat…

No recent releases where the company itself is speaking.

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 12. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Article counts from the last market-wide feed page, across every symbol we track and not just PACB · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.